Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pegylated GCSF Clear all
Recruiting Phase 3 Interventional

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

NCT02582697
View directory record Official record
Conditions
Germ Cell Tumor
Interventions
Bleomycin (active name: Bleomycin Sulfate), Etoposide, Cisplatin, Pegylated G-CSF (Pegfilgrastim), Filgrastim
Drug
Lead sponsor
University of Sydney
Other
Eligibility
11 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
21
States / cities
Downey, California • Loma Linda, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

NCT02390843
View directory record Official record
Conditions
Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 29 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Not listed Phase 2 Interventional

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

NCT04672005
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Drug
Lead sponsor
Lyudmyla Berim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

NCT04196010
View directory record Official record
Conditions
Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Early Phase 1 Interventional

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

NCT02392039
View directory record Official record
Conditions
Lymphoma
Interventions
Pegfilgrastim, Loratadine, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

NCT00953420
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Docetaxel, Carboplatin, Dexamethasone, EBV-specific cytotoxic T lymphocytes, G-CSF or Peg-GCSF
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

NCT03206229
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PEG-rhG-CSF, Neulasta (PEG-rhG-CSF)
Drug
Lead sponsor
Adello Biologics, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 1 Interventional

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

NCT04323956
View directory record Official record
Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

NCT00148317
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, dexamethasone, liposomal doxorubicin, cyclophoshamide, filgrastim
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

NCT01446458
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
Interventions
Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 25, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

NCT01783535
View directory record Official record
Conditions
Retinoblastoma
Interventions
vincristine, topotecan, filgrastim, PEG-filgrastim, carboplatin, focal therapy, etoposide, cyclophosphamide, MESNA, doxorubicin, enucleation, external beam radiation or proton beam radiation
Drug · Other · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

NCT02649673
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer
Interventions
LCL161, Topotecan, Pegylated GCSF (PEG-GCSF)
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

NCT00389818
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

NCT02392793
View directory record Official record
Conditions
Childhood Solid Tumors
Interventions
Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 25 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586
View directory record Official record
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT06709495
View directory record Official record
Conditions
Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim
Drug · Biological
Lead sponsor
David S Shulman, MD
Other
Eligibility
12 Years to 49 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00069953
View directory record Official record
Conditions
Esophageal Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
97
States / cities
Burbank, California • Hayward, California • Mission Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

NCT01523457
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions
Folfirinox
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

NCT04370301
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT02375204
View directory record Official record
Conditions
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
Interventions
paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
14 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

NCT04871607
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Basiliximab, Carmustine, Cytarabine, Etoposide, Genetically Engineered Hematopoietic Stem Progenitor Cells, Recombinant Granulocyte Colony-Stimulating Factor, Yttrium Y 90 Basiliximab
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 25, 2026, 2:12 PM EDT